MyECheck, Inc. (OTC Pink: MYEC) (PINKSHEETS: MYEC), an electronic payment solutions provider and the leader in fully electronic check technology today announced financial results and issues its annual report for 2013. For the twelve months ended December 31, 2013, net profit was $1,018,693 with revenue from operations at $439,233. Total liabilities were reduced by $718,365. For the 3 months ended December 31, 2013 (Q4), net profit...
Monday, March 31, 2014
Novacab International Inc. Announces Pilot Project With Papineau Transport
Novacab International Inc. (OTC Pink: NVOB) (PINKSHEETS: NVOB) is pleased to announce, the Pilot Project with Papineau Transport International using the Novacab System. The fuel economy, using the Novacab System having been validated by Transport Canada, this specific Pilot project is monitored by a telemetric system. Papineau Transport International and immediate affiliates manages more than 100/175 combined Class 8 trucks just at one...
Innovative Food Holdings, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results
Innovative Food Holdings (OTCQB:IVFH), a leading nationwide provider of specialty foods, healthcare foods, gluten free foods, and direct from source artisanal foods, to the professional foodservice market, today announced financial results for the fourth quarter and year ended December 31, 2013. The Company will host an investor conference call at 5:00 pm EDT today to discuss...
Innovative Food Holdings, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results
Innovative Food Holdings (OTCQB:IVFH), a leading nationwide provider of specialty foods, healthcare foods, gluten free foods, and direct from source artisanal foods, to the professional foodservice market, today announced financial results for the fourth quarter and year ended December 31, 2013. The Company will host an investor conference call at 5:00 pm EDT today to discuss...
Rosetta Genomics Reports 2013 Financial Results
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today reported financial results for the year ended December 31, 2013. Highlights for the second half of 2013 and recent weeks include: Continued to enhance awareness of and demand for the Rosetta Cancer Origin Test™, which resulted...
